Research map: From staining to strategy: Making BCL-2 immunohistochemistry in chronic myeloid leukemia clinically actionable and globally scalable

Back to the article

Papers in this map

  1. The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy · Meike Vogler · 2025 · 376 citations · Cited by this paper
  2. Clinical significance of aberrant expression of CD56 on newly diagnosed adult acute myeloid leukemia blast cells · 2025 · Related
  3. Management of chronic myeloid leukemia in 2023 – common ground and common sense · Jayastu Senapati · 2023 · 184 citations · Cited by this paper
  4. Epigenetic regulation of the TET2 gene in Iraqi patients with acute myeloid leukemia: Expression and methylation analysis · 2026 · Related
  5. Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial · Mhairi Copland · 2021 · 59 citations · Cited by this paper
  6. Interleukin-35-driven immune evasion in acute myeloid leukemia: Correlation with circulating (CD3+ CD56+) lymphocyte · 2025 · Related
  7. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial · Nicholas James Short · 2024 · 21 citations · Cited by this paper
  8. Filgrastim-induced cutaneous vasculitis in a patient undergoing stem cell mobilization · 2025 · Related
  9. Immunohistochemical expression of BCL-2 oncogene in chronic myeloid leukemia in Iraqi patients · AreejEmad Kadhom · 2025 · 1 citation · Cited by this paper
  10. Shorting of existing conditioning regimen for relapsed/refractory gastric diffuse large B-cell lymphoma transplant and studying its related outcomes: A first of its kind case report · 2025 · Related
  11. The risk of pulmonary hypertension in sickle cell disease in relation to the disease severity · 2025 · Related
  12. Evaluation of the level of endothelin-1 and tumor necrosis factor-alpha in patients with sickle cell disease · 2026 · Related
  13. Advancement in thrombosis management: Three-dimensional bioprinting technology for precision anticoagulant dosing · 2025 · Related
  14. Investigating the role of red cell and platelet distribution width-to-platelet ratios in diagnosing early-onset neonatal sepsis · 2025 · Related

Source: OpenAlex (CC0)